neuroblastoma-info.blogspot.com
Neuroblastoma Information Research: September 2011
http://neuroblastoma-info.blogspot.com/2011_09_01_archive.html
Thursday, September 29, 2011. COG, Apeiron to conduct APN301 trial in neuroblastoma patients. Children´s Oncology Group (COG) and Apeiron Biologics AG (Apeiron) will jointly investigate Apeiron´s APN301 in a clinical phase II study in pediatric neuroblastoma patients. APN301 is a recombinant fusion protein consisting of the humanized anti-GD2 monoclonal antibody hu14.18 fused to the cytokine interleukin-2 (IL2). APEIRON Biologics AG (Apeiron) and the Children's Oncology Group (COG) today announced a coll...
neuroblastoma-info.blogspot.com
Neuroblastoma Information Research: March 2008
http://neuroblastoma-info.blogspot.com/2008_03_01_archive.html
Monday, March 31, 2008. Serum Neuron-Specific Enolase as a Marker Useful for Monitoring the Effectiveness of Therapy in Patients with Neuroblastoma. Serum Neuron-Specific Enolase as a Marker Useful for Monitoring the Effectiveness of Therapy in Patients with Neuroblastoma. As Compared with Urinary Catecholamine Metabolites. KUMIKO HASHIMOTO1), YOH-ICHI GOTOH1) and KEIYA TADA1). 1) Department of Pediatrics, Tohoku University School of Medicine. Sunday, March 30, 2008. Our results show that Myc proteins ca...
neuroblastoma-info.blogspot.com
Neuroblastoma Information Research: COG, Apeiron to conduct APN301 trial in neuroblastoma patients
http://neuroblastoma-info.blogspot.com/2011/09/cog-apeiron-to-conduct-apn301-trial-in.html
Thursday, September 29, 2011. COG, Apeiron to conduct APN301 trial in neuroblastoma patients. Children´s Oncology Group (COG) and Apeiron Biologics AG (Apeiron) will jointly investigate Apeiron´s APN301 in a clinical phase II study in pediatric neuroblastoma patients. APN301 is a recombinant fusion protein consisting of the humanized anti-GD2 monoclonal antibody hu14.18 fused to the cytokine interleukin-2 (IL2). APEIRON Biologics AG (Apeiron) and the Children's Oncology Group (COG) today announced a coll...
neuroblastoma-info.blogspot.com
Neuroblastoma Information Research: June 2012
http://neuroblastoma-info.blogspot.com/2012_06_01_archive.html
Sunday, June 10, 2012. Neuroblastoma Immunotherapy by Paul M. Sondel, MD, PhD. Lecture by Paul M. Sondel, MD, PhD We are pursuing basic, preclinical and clinical mechanisms to induce in vivo activated innate immune effector cells to provide anti-tumor benefit. Subscribe to: Posts (Atom). Neuroblastoma Immunotherapy by Paul M. Sondel, MD,. Abdullah Umair (Stage 4). View my complete profile.
neuroblastoma-info.blogspot.com
Neuroblastoma Information Research: June 2009
http://neuroblastoma-info.blogspot.com/2009_06_01_archive.html
Saturday, June 27, 2009. Targeted Therapy for Neuroblastoma on the Anvil After Detection of Genetic Glitch. A genetic glitch responsible for the development of the fatal childhood cancer, neuroblastoma, has been identified by scientists from University of Florida. They hope that the new discovery may provide a novel approach for developing treatments that target the disease also known as neuroblastoma. They looked at the genetic makeup of 846 patients with neuroblastoma and 803 healthy patients in a cont...
neuroblastoma-info.blogspot.com
Neuroblastoma Information Research: Targeted Therapy for Neuroblastoma on the Anvil After Detection of Genetic Glitch
http://neuroblastoma-info.blogspot.com/2009/06/targeted-therapy-for-neuroblastoma-on.html
Saturday, June 27, 2009. Targeted Therapy for Neuroblastoma on the Anvil After Detection of Genetic Glitch. A genetic glitch responsible for the development of the fatal childhood cancer, neuroblastoma, has been identified by scientists from University of Florida. They hope that the new discovery may provide a novel approach for developing treatments that target the disease also known as neuroblastoma. They looked at the genetic makeup of 846 patients with neuroblastoma and 803 healthy patients in a cont...
neuroblastoma-info.blogspot.com
Neuroblastoma Information Research: June 2011
http://neuroblastoma-info.blogspot.com/2011_06_01_archive.html
Monday, June 6, 2011. Children With Neuroblastoma Helped by New Chemo Regimen. The trial involved 563 children - median age 3. After three years, the survival was 60 percent for those receiving busulphan-melphalan compared to 48 percent for the CEM group "and the busulphan group had lower rates of relapse and progression.". Previously, only 30 percent of children with high-risk neuroblastoma survive long-term. The study's results show that survival can increase by 20 percent. Myeloablative chemotherapy i...
neuroblastoma-info.blogspot.com
Neuroblastoma Information Research: April 2008
http://neuroblastoma-info.blogspot.com/2008_04_01_archive.html
Sunday, April 20, 2008. Lytic Bone Lesions in Human Neuroblastoma Xenograft Involve Osteoclast Recruitment and Are Inhibited by Bisphosphonate. Yasuyoshi Sohara, Hiroyuki Shimada, Miriam Scadeng, Harvey Pollack, Shinya Yamada, Wei Ye,. C Patrick Reynolds, and Yves A. DeClerck2. Source: http:/ cancerres.aacrjournals.org/cgi/reprint/63/12/3026.pdf. Saturday, April 5, 2008. Curcumin induces apoptosis in human neuroblastoma cells via inhibition of NFkappaB. CONCLUSION: Our results suggest that curcumin might...